Norlase
Debt Financing in 2025
Norlase is a global ophthalmic medical device company specializing in next-generation laser solutions for retina and glaucoma treatments. They offer innovative products like ECHO, the world's first portable pattern laser with wireless capabilities and voice control, and LEAF, an ultra-compact green laser photocoagulator that attaches directly to slit lamps.
TRUMPF
Debt Financing in 2022
TRUMPF is a high-technology company that manufactures sheet metal fabrication machinery, power tools, industrial lasers, and medical technologies. It provides production solutions across machine tool, laser and electronics sectors and drives digital connectivity in manufacturing through consulting, platforms and software offerings. As an independent, family-owned business, TRUMPF operates with a long-term perspective and sustains its innovative strength. The company serves global markets and is recognized as a leader in machine tools and laser technology, delivering systems such as laser cutting, welding, marking and additive production equipment that optimize upstream and downstream manufacturing processes.
DyeMansion
Venture Round in 2022
Founded in Munich, Germany in 2013, DyeMansion specializes in transforming raw, 3D-printed polymer parts into high-value consumer and industrial products. The company offers precision coloring and finishing systems that work with major industrial powder-bed 3D printing systems, enabling high-volume production for diverse applications.
Brolis Sensor Technology
Debt Financing in 2021
Brolis Sensor Technology is a specialized company focused on developing and manufacturing advanced spectroscopic sensors tailored for medical and fitness applications. Established in 2019 as a distinct entity within Brolis Group, the company offers ultra-compact, laser-based integrated sensor systems capable of multi-molecule sensing throughout the bloodstream. This innovative technology empowers individuals to monitor their health more effectively, promoting personalized healthcare solutions that enhance overall well-being.
Nanobiotix SA is a clinical-stage biotechnology company based in Paris, France, focused on advancing cancer treatment through its innovative nanomedicine programs. The company is known for its proprietary NanoXray technology, which enhances the effectiveness of radiotherapy by amplifying its impact on tumor cells while minimizing exposure to surrounding healthy tissues. One of its key products, NBTXR3, is a radio-enhancer composed of hafnium oxide designed for treating various solid tumors, including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, and glioblastoma. Founded in 2003, Nanobiotix is dedicated to transforming cancer therapy and improving patient outcomes using its advanced nanotechnology solutions.
Nanobiotix SA is a clinical-stage biotechnology company based in Paris, France, focused on advancing cancer treatment through its innovative nanomedicine programs. The company is known for its proprietary NanoXray technology, which enhances the effectiveness of radiotherapy by amplifying its impact on tumor cells while minimizing exposure to surrounding healthy tissues. One of its key products, NBTXR3, is a radio-enhancer composed of hafnium oxide designed for treating various solid tumors, including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, and glioblastoma. Founded in 2003, Nanobiotix is dedicated to transforming cancer therapy and improving patient outcomes using its advanced nanotechnology solutions.